Filing Flows › Mereo BioPharma Group (MREO) › Guidance & outlook

Mereo BioPharma Group (MREO) guidance and outlook

Mereo BioPharma Group's 10-Q filed Nov 9, 2026 makes 11 forward-looking statements.

Guidance and outlook

Forward-looking statements, 10-Q filed Nov 9, 2026

• Under the current business plan and cash flow forecasts, and in consideration of our ongoing research and development efforts and our general corporate funding requirements, we anticipate that our current on-hand cash resources will extend into late 2027.
• However, we will need additional external funding or may need to implement measures to conserve cash resources to complete our development plans and potentially commercialize selected rare disease products.
• We plan to fund our operations through cash on hand and a combination of non-dilutive funding sources, including partnering income, public or private equity or debt financing, or other sources.
• We expect to continue to report significant operating losses for the foreseeable future as we continue our research and development efforts and seek to obtain regulatory approval of our product candidates and any future product candidates we develop.
• We expect to continue to incur expenses in connection with our ongoing development activities related to our product candidates, our outsourced manufacturing activities and other associated costs including the management of our intellectual property portfolio.
• We also expect to continue to incur costs associated with operating as a U.S. public company listed on Nasdaq and as a domestic registrant.
• These costs will increase further if we:
• We expect that our existing cash and cash equivalents will enable us to fund our currently committed clinical trials, operating expenses and capital expenditure requirements into late 2027.
• We have based these estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect.
• Our revenues, if any, will be derived from milestones, royalties or direct commercial sales of any product candidates that we or our partners are able to successfully develop, receive regulatory approval for, and commercialize in future years.
• In the meantime, we will need to obtain substantial additional funds to achieve our business objective.

Mereo BioPharma Group's latest quarter

Questions

What does Mereo BioPharma Group expect?

Under the current business plan and cash flow forecasts, and in consideration of our ongoing research and development efforts and our general corporate funding requirements, we anticipate that our current on-hand cash resources will extend into late 2027. However, we will need additional external funding or may need to implement measures to conserve cash resources to complete our development plans and potentially commercialize selected rare disease products. We plan to fund our operations through cash on hand and a combination of non-dilutive funding sources, including partnering income, publi

Open the interactive view →

Updated Nov 9, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.